Does omalizumab therapy for patients with moderate to severe allergic asthma affect these patients’ use of antitussives?
All articles by Virginia A. Schad, PharmD, RPh
What is the difference in efficacy between mepolizumab and benralizumab, 2 biologics approved for the treatment of severe eosinophilic asthma?
Does pulmonary inflammation resulting from airborne toxicants trigger immune system activation in individuals with asthma and COPD?
A post-hoc analysis compared lung function changes in the INCREASE and TRIUMPH trials of inhaled treprostinil for PH-ILD and PAH.
Researchers conducted subgroup analysis of revenfenacin phase 3 trial data to assess health status improvements in women vs men with moderate to severe COPD.
Mepolizumab reduces disease symptoms in patients with chronic rhinosinusitis with nasal polyps, according to the results of a randomized, double-blind, multicenter study.
Berotralstat may reduce the use of on-demand medications in patients with hereditary angioedema (HAE) who were previously treated with prophylactic therapies.
In patients with moderate to severe chronic rhinosinusitis with nasal polyposis, treatment with an Exhalation Delivery System With Fluticasone (EDS-FLU) is associated with improved sleep scores.
Active eosinophilic esophagitis appears to be associated with lower lung function and increased asthma severity in children with comorbid asthma.
Dupilumab significantly reduced severe asthma exacerbations and improved prebronchodilator FEV1 in patients with baseline FeNO greater than or equal to 25 ppb with/without substantial FeNO reduction.